IRLAB receives acceptance for two abstracts at AD/PD™ 2026: The 20th International Conference on Alzheimer’s and Parkinson’s Diseases
Gothenburg, Sweden, November 7, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that two abstracts have been accepted for presentation at the international conference AD/PD 2026, to be held in Copenhagen on March 17–21.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 14, 2025. https://www.redeye.se/video/event-presentation/1130614/irlab-therapeuti%E2%80%A6-2025-october-15?embed
Read More >